![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
TU2670 (merigolix) is a once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist, which is being investigated in females with endometriosis-associated-pain.
Lead Product(s): Merigolix
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: TU2670
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 08, 2024
Details:
TU7710, a novel recombinant activated factor VII (rFVIIa) for hemophilia patients with inhibitors. It is being evaluated in the Phase I clinical trial studies for the treatment of Hemophilia A & B and also Blood Coagulation Disorders.
Lead Product(s): TU7710
Therapeutic Area: Genetic Disease Product Name: TU7710
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2024
Details:
The proceeds will be primarily allocated to support TiumBio's clinical programs that include a Phase 2 trial of TU2670 (merigolix), a once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in endometriosis.
Lead Product(s): Merigolix
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: TU2670
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: SK Chemicals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Private Placement December 29, 2023
Details:
TU2670 is an orally active non-peptide GnRH antagonist currently undergoing a Phase 2a clinical study in the EU for the treatment of moderate to severe pain associated with endometriosis.
Lead Product(s): HS-10518
Therapeutic Area: Neurology Product Name: TU2670
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hansoh Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 05, 2023
Details:
Under this agreement, Oncodesign will be responsible for identification, chemical synthesis and optimization of Nanocyclix drug candidates and their early-stage analysis, while TiumBio will be responsible for the advanced evaluation of fibrotic efficacy of the drug candidates.
Lead Product(s): Nanocyclix Drug Candidates
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Oncodesign
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 21, 2021